The safety of spironolactone treatment in patients with heart failure

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 4, 2003, Pages 285-287

  Anton, C ^a   Cox, A R ^a   Watson, R D S ^a   Ferner, R E ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

ACE inhibitor; Angiotensin 2 receptor antagonist; Drug drug interaction; Heart failure; Hyperkalaemia; Spironolactone

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM; SPIRONOLACTONE;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEMATOCRIT; HUMAN; HYPERKALEMIA; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALS, TEACHING; HUMANS; HYPERKALEMIA; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 2; RETROSPECTIVE STUDIES; RISK FACTORS; SPIRONOLACTONE; SURVIVAL RATE;

EID: 0042881056     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00491.x     Document Type: Article

References (7)

1. Pitt B, Zannad F, Remme WJ et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New England Journal of Medicine, 341, 709-717.
2. McMurray J, Cohen-Solal A, Dietz R et al. (2001) Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. European Journal of Heart Failure, 3, 495-502.
3. Schepkens H, Vanholder R, Billiouw JM, Lameire N (2001) Life-threatening hyperkalaemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. American Journal of Medicine, 110, 438-441.
4. Georges B, Beguin C, Jadoul M (2000) Spironolactone and congestive heart failure. Lancet, 355, 1369-1370.
5. Berry C, McMurray JJV (2001) Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart, 85, e8.
6. Bouvy ML, Eibert RH, Herings RMC (2001) Long term therapy with spironolactone. Pharmacy World and Science, 23, 132-134.
7. Pitt B, Perez A (2000) Spironolactone in patients with heart failure. New England Journal of Medicine, 342, 133-134.